Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
October 31, 2024 07:30 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...